Charles River/$CRL

13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX

About Charles River

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Ticker

$CRL
Sector

Primary listing

NYSE

Employees

19,400

Charles River Metrics

BasicAdvanced
$8.2B
-
-$1.37
1.50
-

What the Analysts think about Charles River

Analyst ratings (Buy, Hold, Sell) for Charles River stock.

Bulls say / Bears say

Second-quarter revenue rose to $1.032 billion, an increase of 0.6% year-over-year, and non-GAAP EPS climbed 11.4% to $3.12, boosted by improved operating margins in all divisions (Business Wire)
The company raised its full-year 2025 revenue and non-GAAP EPS guidance after better-than-expected Q2 results, reflecting management’s confidence in stronger market conditions (Business Wire)
U.S. Department of Justice concluded both grand jury and civil investigations into Charles River’s non-human primate supply chain, eliminating a major legal uncertainty (Business Wire)
Discovery & Safety Assessment segment’s organic revenue declined 2.4% year-over-year in Q2, indicating ongoing weak demand for Charles River’s key drug discovery services (Business Wire)
Manufacturing Solutions segment’s GAAP operating margin fell sharply to 6.0% from 19.4% year-over-year in Q2, due to accelerated amortization of CDMO client relationships, exposing volatility in segment profitability (Business Wire)
The agreement with Elliott Investment Management to appoint four new directors and conduct a strategic review signals ongoing governance issues and uncertainty around the company’s strategic direction (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2025.

Charles River Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Charles River Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CRL

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs